- cafead   Sep 08, 2020 at 11:02: PM
via Aveo Oncology has regained the full global rights to ficlatuzumab. Biodesix was co-developing the hepatocyte growth factor inhibitory antibody with Aveo but has chosen to exercise its opt-out right before the program moves into phase 3.
article source
article source